Oncotarget: Sirolimus-eluting stents -- opposite in vitro effects on the clonogenic cell potential

October 21, 2020

The cover for issue 31 of Oncotarget features Figure 4, "Concentration dose-response curves of sirolimus effect [55 nM–1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure," by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.

Three cell lines were selected and growth in 10 ml of Minimum Essential Medium for 5 weeks with serial dilutions of sirolimus.

The number of colonies and the number of cells per colony were counted.

As a result, the number of WPMY-1 surviving colonies increased in a dose-dependent manner when treated with sirolimus, while the number of U2OS colonies progressively decreased.

In conclusion sirolimus showed the well-known cytostatic effect, but with an effect on clonogenic potential different among the different cell types.

Dr. Gianandrea Pasquinelli from The Bologna University said, "Rapamycin (sirolimus) is a widely used cytostatic drug blocking the cell cycle in the phase G1/S through the inhibition of the mammalian target of Rapamycin (mTOR) pathway, that has found several clinical applications, from immunosuppression in diabetes and organ transplantation to cancer therapy and drug-eluting stents (DES)"

Beside to its cytostatic activity, sirolimus was also discovered to protect normal human oral keratinocytes from apoptosis by activating autophagy, and to act as a basal stem cell keratinocyte-protecting drug in irradiated mice.

The effect of sirolimus on mesenchymal cells is unknown, but it is an important issue, since mesenchymal cells such as myofibroblasts and cells promoting vascular calcification play an important role in atherogenesis and vascular restenosis.

Sirolimus seems to block the proliferation and the migration of vascular smooth muscle cells, but we lack information concerning the effects on other cells composing atherosclerotic plaques.

The aim of the present paper is to evaluate the long-term effects of sirolimus, rather than short-term cell survival, on three different cell in vitro models, cultured in Minimum Essential Medium, which simulates physiological conditions (w/o CO2 and glucose, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.

The Pasquinelli Research Team concluded in their OncotargetResearch Paper that the plaque typology and the different cell composition of the plaque, e. g., the presence of inflammatory cells, angiogenesis, prevalence of fibrosis, presence of osteogenic progenitors, may influence the response to sirolimus.

"The presence of inflammatory cells, angiogenesis, prevalence of fibrosis, presence of osteogenic progenitors, may influence the response to sirolimus"


Moreover, it is known that the clonal capacity varies between cells and we should consider this matter when evaluating the effectiveness of eluted stent.

Finally, additional mechanisms can have a role, such as amitotic cell division.

These mechanisms were also observed in human atherogenesis and could be fundamental to evaluate the in vivo effect of sirolimus too.
-end-
Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27554

Full text - https://www.oncotarget.com/article/27554/text/

Correspondence to - Gianandrea Pasquinelli - gianandr.pasquinelli@unibo.it

Keywords - atherosclerosis, cell proliferation, sirolimus, stents

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud -https://soundcloud.com/oncotarget
Facebook -https://www.facebook.com/Oncotarget/
Twitter -https://twitter.com/oncotarget
LinkedIn -https://www.linkedin.com/company/oncotarget
Pinterest -https://www.pinterest.com/oncotarget/
Reddit -https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105

Impact Journals LLC

Related Sirolimus Articles from Brightsurf:

Oncotarget: Sirolimus-eluting stents -- opposite in vitro effects on the clonogenic cell potential
The cover for issue 31 of Oncotarget features Figure 4, ''Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,'' by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.

Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial.

Little-used drug combination may extend the lives of lung transplant patients
Median survival after lung transplant is less than six years.

IDIBELL researchers successfully test a new combination therapy in sarcomas
Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults.

What are risk factors for melanoma in kidney transplant recipients?
Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by JAMA Dermatology.

UC research examines lung cell turnover as risk factor & target for treatment of influenza pneumonia
Most of the 500,000 annual deaths worldwide from influenza are due to influenza pneumonia.

Northwell Health's Feinstein Institute discovers cancer treatment for transplant patients
Kenar D. Jhaveri, M.D., and Richard Barnett, M.D., Feinstein Institute for Medical Research scientists and Northwell Health Department of Internal Medicine nephrologists, published a Letter to the Editor in the prestigious New England Journal of Medicine, which profiles a novel drug combination with the potential to help prevent rejection of a donor kidney in transplant patients undergoing cancer treatment.

Results from PRISON IV presented at TCT & published in JACC: Cardiovascular Interventions
Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions.

TCT 2016 first reports examine potential for novel bioresorbable stent technologies
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients.

Results from the BIO-RESORT trial presented at TCT 2016 and published in The Lancet
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes.

Read More: Sirolimus News and Sirolimus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.